AMRI expands discovery capabilities in India
As part of a long-term strategic plan to further its discovery capabilities in India, contract research and manufacturer AMRI (NASDAQ:AMRI) has hired two experts in medicinal and computational chemistry at its research center in Hyderabad, India (HRC).
The new hires and relocation of resources provide additional flexibility to enhance productivity and client service for AMRI’s global drug discovery operations, which draw upon a broad spectrum of service capabilities from multiple sites.
Srinivas Nanduri was hired as director of medicinal chemistry in India and Suneel Kumar Bommisetty was hired as senior research associate in computational chemistry. The newly created positions will further strengthen AMRI’s capabilities in problem-solving medicinal chemistry and complement its current strength in custom synthesis at HRC.
“AMRI is committed to providing best-of-class services to our customers, and servicing the entire value chain of contract research services,” Subramanyam Maddala, president of India operations said in a statement. “These additions enhance our capabilities to move towards that target.”
Bruce J. Sargent, AMRI’s senior vice president of drug discovery said “strengthening our HRC capabilities is an essential element of our SMARTSOURCING strategy, which brings together the right mix of AMRI global services, capabilities and translational expertise, while maintaining the same high standards for performance, quality and productivity.”